Qushi huayu decoction inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in vivo and in vitro

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Feng, Qin ^a   Gou, Xiao Jun ^a   Meng, Sheng Xi ^a   Huang, Cheng ^b   Zhang, Yu Quan ^b   Tang, Ya Jun ^a   Wang, Wen Jing ^a   Xu, Lin ^a   Peng, Jing Hua ^a   Hu, Yi Yang ^a,c  

^a SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Shanghai Key Laboratory of Traditional Chinese Clinical Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; FAT DROPLET; FATTY ACID; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; JASMINOIDIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUCLEAR PROTEIN; POLYGONIN; QUSHI HUAYU; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHINESE HERB; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID DIET; LIPID STORAGE; LIPOGENESIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 84876584103     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/184358     Document Type: Article

References (30)

1. Cohen J. C., Horton J. D., Hobbs H. H., Human fatty liver disease: old questions and new insights. Science 2011 332 6037 1519 1523 2-s2.0-79959517565 10.1126/science.1204265
2. Targher G., Chonchol M., Pichiri I., Zoppini G., Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? Journal of Endocrinological Investigation 2011 34 544 551
3. Lewis J. R., Mohanty S. R., Nonalcoholic fatty liver disease: a review and update. Digestive Diseases and Sciences 2010 55 3 560 578 2-s2.0-77949311823 10.1007/s10620-009-1081-0
4. Torres D. M., Williams C. D., Harrison S. A., Features, diagnosis, and treatment of nonalcoholic Fatty liver disease. Clinical Gastroenterology and Hepatology 2012 10 837 858
5. Postic C., Girard J., The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes & Metabolism 2008 34 6 643 648 2-s2.0-62749188867 10.1016/S1262-3636(08)74599-3
6. Long Y. C., Zierath J. R., AMP-activated protein kinase signaling in metabolic regulation. Journal of Clinical Investigation 2006 116 7 1776 1783 2-s2.0-33745815985 (Pubitemid 44033297)
7. Ha S. K., Kim J., Chae C., Role of AMP-activated protein kinase and adiponectin during development of hepatic steatosis in high-fat diet-induced obesity in rats. Journal of Comparative Pathology 2011 145 1 88 94 2-s2.0-79955993481 10.1016/j.jcpa.2010.11.011
8. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., Hue L., Andreelli F., Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. Journal of Physiology 2006 574 1 41 53 2-s2.0-33745196745 10.1113/jphysiol.2006.108506 (Pubitemid 43905795)
9. Foretz M., Ancellin N., Andreelli F., Saintillan Y., Grondin P., Kahn A., Thorens B., Vaulont S., Viollet B., Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005 54 5 1331 1339 2-s2.0-17844368938 10.2337/diabetes.54.5.1331 (Pubitemid 40586661)
10. Browning J. D., Horton J. D., Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 2004 114 2 147 152 2-s2.0-4043077961 10.1172/JCI200422422 (Pubitemid 39071617)
11. Guillou H., Martin P. G., Pineau T., Transcriptional regulation of hepatic fatty acid metabolism. Sub-Cellular Biochemistry 2008 49 3 47 2-s2.0-58149314594
12. Dowman J. K., Armstrong M. J., Tomlinson J. W., Newsome P. N., Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011 13 8 692 702 2-s2.0-79959466159 10.1111/j.1463-1326.2011. 01403.x
13. Mu Y., Du J., Liu P., Herbal prescription experience in the treatment of non-alcoholic steatohepatitis of Professor Liu Ping. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2009 19 170 171
14. Zhang H., Feng Q., Li H. S., Chen S. D., Wang X. N., Peng J. H., Zhang N., Hu Y. Y., Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor expression in rats with non-alcoholic steatohepatitis. Journal of Chinese Integrative Medicine 2008 6 9 928 933 2-s2.0-52949139785 10.3736/jcim20080910
15. Feng Q., Cheng Y., Hu Y. Y., Zhang H., Peng J. H., Zhang N., Qushi Huayu Decoction inhibits protein and gene expression of cathepsin B in HepG2 cells induced by free fatty acids. Chinese Journal of Integrative Medicine 2010 16 6 518 524 2-s2.0-79952541848 10.1007/s11655-010-0568-z
16. Kleiner D. E., Brunt E. M., Van Natta M., Behling C., Contos M. J., Cummings O. W., Ferrell L. D., Liu Y. C., Torbenson M. S., Unalp-Arida A., Yeh M., McCullough A. J., Sanyal A. J., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313 1321 2-s2.0-20044374023 10.1002/hep.20701 (Pubitemid 40770284)
17. Meng Z. Z., Hu J. H., Chen J. X., Yue G. X., Xiaoyaosan decoction, a traditional chinese medicine, inhibits oxidative-stress-induced hippocampus neuron apoptosis in vitro. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 489254 10.1155/2012/489254
18. Heider J. G., Boyett R. L., The picomole determination of free and total cholesterol in cells in culture. Journal of Lipid Research 1978 19 4 514 518 2-s2.0-0018185320 (Pubitemid 8356055)
19. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006 127 6 1109 1122 2-s2.0-33845399894 10.1016/j.cell.2006.11.013 (Pubitemid 44894520)
20. Lee M. S., Kim C. T., Kim Y., Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. Annals of Nutrition and Metabolism 2009 54 2 151 157 2-s2.0-65449125891 10.1159/000214834
21. Kim W. S., Lee Y. S., Cha S. H., Jeong H. W., Choe S. S., Lee M. R., Oh G. T., Park H. S., Lee K. U., Lane M. D., Kim J. B., Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. American Journal of Physiology 2009 296 4 E812 E819 2-s2.0-65649089100 10.1152/ajpendo.90710.2008
22. Feldstein A. E., Werneburg N. W., Canbay A., Guicciardi M. E., Bronk S. F., Rydzewski R., Burgart L. J., Gores G. J., Free fatty acids promote hepatic lipotoxicity by stimulating TNF- expression via a lysosomal pathway. Hepatology 2004 40 1 185 194 2-s2.0-3042824524 10.1002/hep.20283 (Pubitemid 38868937)
23. Feldstein A. E., Werneburg N. W., Li Z., Bronk S. F., Gores G. J., Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. American Journal of Physiology 2006 290 6 G1339 G1346 2-s2.0-33646891970 10.1152/ajpgi.00509.2005 (Pubitemid 43788317)
24. Skrobuk P., von Kraemer S., Semenova M. M., Zitting A., Koistinen H. A., Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells. Diabetologia 2012 55 3051 3060
25. Do G. M., Jung U. J., Park H. J., Kwon E. Y., Jeon S. M., McGregor R. A., Choi M. S., Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Molecular Nutrition & Food Research 2012 56 1282 1291
26. Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A., Prabhu V. V., Allard J. S., Lopez-Lluch G., Lewis K., Pistell P. J., Poosala S., Becker K. G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K. W., Spencer R. G., Lakatta E. G., Le Couteur D., Shaw R. J., Navas P., Puigserver P., Ingram D. K., De Cabo R., Sinclair D. A., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006 444 7117 337 342 2-s2.0-33751072349 10.1038/nature05354 (Pubitemid 44764104)
27. Vinson J. A., Burnham B. R., Nagendran M. V., Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes, Metabolic Syndrome and Obesity 2012 5 21 27
28. Kojima K., Shimada T., Nagareda Y., Watanabe M., Ishizaki J., Sai Y., Miyamoto K., Aburada M., Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells. Biological and Pharmaceutical Bulletin 2011 34 1613 1618
29. Ong K. W., Hsu A., Tan B. K., Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. PLoS ONE 2012 7 e32718
30. Ma T., Huang C., Zong G., Zha D., Meng X., Li J., Tang W., Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. Journal of Pharmacy and Pharmacology 2011 63 4 587 593 2-s2.0-79952715994 10.1111/j.2042-7158.2011.01256.x